Theriva Biologics, Inc. (TOVX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Theriva Biologics, Inc. (TOVX) closed at USD 0.21 on 2026-10-15, a change of -32.3 % over the past year, with a market capitalization of USD 9.54M.

Theriva Biologics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Theriva Biologics, Inc. key figures

Previous close

USD 0.21 (2026-10-15)

1-year change

-32.3 %

Market cap

USD 9.54M

Enterprise value

USD 1.76M

P/E ratio (trailing)

0.29

P/E ratio (forward)

-1.04

EPS (trailing)

0.73

EPS (forward)

-0.20

PEG ratio

n/a

Price to book

0.78

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

3.69

Employees

15

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Theriva Biologics, Inc.

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Theriva Biologics, Inc. and compare it with other stocks.